Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF/VI vs Tiotropium on Arterial Stiffness in COPD
NCT01395888Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2011
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of fluticasone furoate + vilanterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Mean Change From Baseline in Aortic Pulse Wave Velocity at 12 weeks. Started Jun 2011; status: completed.
02
Drugs
fluticasone furoate + vilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01395888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01395888.